Australia’s first needle-free adrenaline spray approved for anaphylaxis
20 Jan 2026
The product, called neffy, is approved for adults and children aged four years and older who weigh at least 15 kg.
Traditionally, adrenaline has been delivered via injection, including with devices such as the EpiPen. The nasal spray provides a small, easy-to-use alternative that delivers the medicine through the nasal lining into the bloodstream. According to manufacturer CSL Seqirus, the spray is generally well tolerated, with the most common side effects being mild nasal irritation and headache.
Allergist Professor Connie Katelaris welcomed the new treatment. “Allergic conditions affect roughly 30 per cent of Australians and can place a real burden on individuals and families,” she said. “Anaphylaxis is the most serious type of allergic reaction. Having another treatment option is a big step forward. The nasal spray has already been used overseas, and it’s great to see it now available here.”
Needle-free nasal sprays are becoming more common in Australia. Similar products are being used for flu vaccination, opioid overdose reversal, sleep apnoea, and research into treatments for depression.
Data from the Australian Commission on Safety and Quality in Health Care highlights the growing impact of anaphylaxis, with emergency visits rising 51 per cent and hospital admissions increasing 35 per cent between 2015 and 2020.
The Australasian Society of Clinical Immunology and Allergy (ASCIA) is updating its guidelines and training to support healthcare professionals in using the new spray. Associate Professor Kristina Rueter, Chair of the ASCIA Anaphylaxis Committee, said the nasal spray represents “the most significant development in anaphylaxis management in over 20 years.”
The nasal spray will be available from February as a Schedule 4 medicine on private prescription. CSL Seqirus has also applied for a PBS listing, with consideration expected in March. Dr Jonathan Anderson, GP and Executive Medical Director at CSL Seqirus, said: “We hope this new option will make it easier for Australians at risk of anaphylaxis to access treatment and give healthcare professionals more flexibility in care.”
https://www1.racgp.org.au/
Source: CSL Seqirus, TGA, ASCIA